The direct and indirect costs of both overweight and obesity: a systematic review

Abstract

BackgroundThe rising prevalence of overweight and obesity places a financial burden on health services and on the wider economy. Health service and societal costs of overweight and obesity are typically estimated by top-down approaches which derive population attributable fractions for a range of conditions associated with increased body fat or bottom-up methods based on analyses of cross-sectional or longitudinal datasets. The evidence base of cost of obesity studies is continually expanding, however, the scope of these studies varies widely and a lack of standardised methods limits comparisons nationally and internationally. The objective of this review is to contribute to this knowledge pool by examining direct costs and indirect (lost productivity) costs of both overweight and obesity to provide comparable estimates. This review was undertaken as part of the introductory work for the Irish cost of overweight and obesity study and examines inconsistencies in the methodologies of cost of overweight and obesity studies. Studies which evaluated the direct costs and indirect costs of both overweight and obesity were included.MethodsA computerised search of English language studies addressing direct and indirect costs of overweight and obesity in adults between 2001 and 2011 was conducted. Reference lists of reports, articles and earlier reviews were scanned to identify additional studies.ResultsFive published articles were deemed eligible for inclusion. Despite the limited scope of this review there was considerable heterogeneity in methodological approaches and findings. In the four studies which presented separate estimates for direct and indirect costs of overweight and obesity, the indirect costs were higher, accounting for between 54% and 59% of the estimated total costs.ConclusionA gradient exists between increasing BMI and direct healthcare costs and indirect costs due to reduced productivity and early premature mortality. Determining precise estimates for the increases is mired by the large presence of heterogeneity among the available cost estimation literature. To improve the availability of quality evidence an international consensus on standardised methods for cost of obesity studies is warranted. Analyses of nationally representative cross-sectional datasets augmented by data from primary care are likely to provide the best data for international comparisons.

Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake

“…Together, these data provide the first evidence that the VTA mediates the interaction of amylin and leptin to cooperatively promote negative energy balance. obesity; mesolimbic; reward; islet amyloid polypeptide OBESITY REPRESENTS A PREVALENT, COSTLY HEALTH PROBLEM in the US and worldwide (11,43,44), yet effective noninvasive treatment options for this disease are extremely limited. Many pharmacotherapeutic strategies to date have attempted to treat obesity by targeting a single feeding-related neuroendocrine system, but the vast majority of these monotherapy approaches have failed to produce meaningful and sustained reductions in body weight (41).…”

Carga financiera del cuidado del enfermo crónico en un grupo de familias en Guatemala

“…La metodología permitió determinar el esfuerzo financiero adicional en la experiencia del cuidado de la salud desde la perspectiva de la familia discriminando los gastos que se asocian con servicios de salud de aquellos que se vinculan directamente al consumo familiar señalando que unos y otros hacen parte de la misma carga del cuidado [37][38][39] .…”

Obesidad y cáncer: fisiopatología y evidencia epidemiológica

“…Después de la menopausia, cuando se suspende la producción de estrógeno ovárico, el tejido adiposo se convierte en la fuente principal de estrógeno endógeno a partir de precursores androgénicos. Mujeres postmenopáusicas obesas tienen mayores tasas de conversión de hormonas sexuales en comparación con mujeres postmenopáusicas no obesas (65,66). En general, las mujeres con niveles circulantes de estrógeno superiores al 20% de lo normal tienen entre 2 y 3 veces más riesgo de padecer cáncer (55,65).…”